Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

more than one focal lesion appears on an MRI scan Many people with myeloma show abnormalities in lab blood tests before they develop symptoms. Multiple myeloma requires active treatment if one or ...

Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die ... invoked for treatment initiation was the presence of bone lesions (n=77), while ...

Abstract: It is quite challenging to visually identify skin lesions with irregular shapes, blurred boundaries and large scale variances. Convolutional Neural Network (CNN) extracts more local features ...

Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg ...

Brain volume loss is a key marker of degeneration in multiple sclerosis ... Keenan and colleagues said traditionally, lesion burden has been used as a surrogate marker for disease activity ...

Despite trial discontinuation, ONCT-534 demonstrated potential in reducing PSA levels and target lesions in some patients. The drug has preclinical activity against unmutated AR and multiple AR ...

Credit: Michael Vi/Shutterstock The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly diagnosed multiple ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...

The following is a summary of “Coexistence of Epilepsy or Seizure and Multiple Sclerosis ... Expanded Disability Status Scale (EDSS), disease-modifying therapies (DMTs), and lesion localization. The ...

Osteolytic bone disease is a frequent complication of multiple myeloma, resulting in skeletal ... Osteolytic bone lesions are the result of excessive bone resorption due to increased osteoclast ...